{"generic":"Topotecan Hydrochloride","drugs":["Hycamtin","Topotecan Hydrochloride"],"mono":[{"id":"923666-s-0","title":"Generic Names","mono":"Topotecan Hydrochloride"},{"id":"923666-s-1","title":"Dosing and Indications","sub":[{"id":"923666-s-1-4","title":"Adult Dosing","mono":"<ul><li>administer only to patients with a baseline neutrophil count 1500 cells\/mm(3) or greater and a platelet count of 100,000 cells\/mm(3) or greater<\/li><li>verify body surface area prior to dispensing<\/li><li><b>Carcinoma of cervix, Stage IVB, recurrent, or persistent; in combination with cisplatin:<\/b> 0.75 mg\/m(2)\/day IV over 30 minutes on days 1, 2, and 3; followed by cisplatin 50 mg\/m(2) IV infusion on day 1; repeat every 21 days; generally do not exceed topotecan 4 mg IV per dose<\/li><li><b>Chronic myelomonocytic leukemia:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Metastatic ovarian tumor, After failure of initial or subsequent chemotherapy:<\/b> 1.5 mg\/m(2)\/day IV over 30 minutes for 5 consecutive days starting on day 1 of a 21-day course, minimum of 4 courses recommended; generally do not exceed 4 mg IV per dose<\/li><li><b>Myelodysplastic syndrome:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Non-small cell lung cancer:<\/b> 1.5 mg\/m(2) IV daily over 30 minutes for 5 days, every 3 weeks<\/li><li><b>Small cell carcinoma of lung, After failure of first-line therapy:<\/b> (IV) 1.5 mg\/m(2)\/day IV over 30 minutes for 5 consecutive days starting on day 1 of a 21-day course; minimum of 4 courses recommended; generally do not exceed 4 mg IV per dose; granulocyte colony-stimulating factor may be given with the next course of therapy starting on day 6 (24 hours from last topotecan dose) if severe neutropenia occurs<\/li><li><b>Small cell carcinoma of lung, After failure of first-line therapy:<\/b> (oral) 2.3 mg\/m(2)\/day ORALLY once daily for 5 consecutive days; repeat every 21 days; round calculated dose to the nearest 0.25-mg capsule and keep the same daily dose each day of treatment<\/li><\/ul>"},{"id":"923666-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"923666-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, serum creatinine greater than 1.5 mg\/dL; treatment of cervical cancer in combination with cisplatin:<\/b> (IV) do not initiate therapy<\/li><li><b>renal impairment, mild (CrCl, 40 to 60 mL\/min):<\/b> (IV) no dosage adjustment needed<\/li><li><b>renal impairment, moderate (CrCl, 20 to 39 mL\/min):<\/b> (IV) adjust dose to 0.75 mg\/m(2) IV<\/li><li><b>renal impairment, mild (CrCl 50 to 79 mL\/min):<\/b> (oral) no dosage adjustment needed<\/li><li><b>renal impairment, moderate (CrCl, 30 to 49 mL\/min):<\/b> (oral) decrease initial dose to 1.5 mg\/m(2)\/day; may titrate by 0.4 mg\/m(2)\/day after first course, depending on tolerability<\/li><li><b>renal impairment, severe (CrCl less than 30 mL\/min):<\/b> (oral) decrease initial dose to 0.6 mg\/m(2)\/day; may titrate by 0.4 mg\/m(2)\/day after first course, depending on tolerability<\/li><li><b>hepatic impairment, serum bilirubin 1.7 to 15 mg\/dL:<\/b> (IV) patients tolerated usual recommended topotecan dosage<\/li><li><b>anemia:<\/b> (oral) interrupt until hemoglobin recovers to 9 g\/dL or greater<\/li><li><b>diarrhea, grade 3 or 4:<\/b> (oral) do not administer; following recovery to grade 1 or less, reduce dose by 0.4 mg\/m(2)\/day for subsequent courses<\/li><li><b>febrile neutropenia (neutrophil count less than 1000 cells\/mm(3) and temperature of 38 degrees C [100.4 degrees F] or greater); treatment of cervical cancer in combination with cisplatin:<\/b> (IV) reduce dose  to 0.6 mg\/m(2) for subsequent courses; alternatively, before reducing topotecan dose, administer granulocyte colony stimulating factor (G-CSF) following the subsequent course, starting from day 4 of the course (24 hours after completion of topotecan administration); if febrile neutropenia occurs despite the use of G-CSF, decrease topotecan dose to 0.45 mg\/m(2) IV for subsequent courses<\/li><li><b>neutropenia (neutrophil count between 500 and 1000 cells\/mm(3) lasting beyond day 21 of the treatment course or neutrophils less than 500 cells\/mm(3) associated with fever, infection, or lasting for 7 days or longer):<\/b> (oral) interrupt until neutrophils recover to greater than 1000 cells\/mm(3) and reduce dose by 0.4 mg\/m(2)\/day for subsequent courses<\/li><li><b>neutropenia, severe (neutrophil count less than 500 cells\/mm(3)), treatment of ovarian or small cell lung cancer:<\/b> (IV) reduce dose to 1.25 mg\/m(2) for subsequent course; alternatively, before reducing topotecan dose, administer granulocyte colony stimulating factor following the subsequent course, starting from day 6 of the course (24 hours after completion of topotecan administration)<\/li><li><b>thrombocytopenia (platelets less than 25,000 cells\/mm(3)):<\/b> (oral) interrupt until platelets recover to greater than 100,000 cells\/mm(3) and reduce dose by 0.4 mg\/m(2)\/day for subsequent courses<\/li><li><b>thrombocytopenia (platelet count less than 25,000 cells\/mm(3)), treatment of cervical cancer in combination with cisplatin:<\/b> (IV) reduce dose to 0.6 mg\/m(2) for subsequent courses<\/li><li><b>thrombocytopenia (platelet count less than 25,000 cells\/mm(3)), treatment of ovarian or small cell lung cancer:<\/b> (IV) reduce dose to 1.25 mg\/m(2) for subsequent courses<\/li><\/ul>"},{"id":"923666-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Carcinoma of cervix, Stage IVB, recurrent, or persistent; in combination with cisplatin<\/li><li>Metastatic ovarian tumor, After failure of initial or subsequent chemotherapy<\/li><li>Small cell carcinoma of lung, After failure of first-line therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cervical cancer, Advanced, recurrent, or persistent; as monotherapy in patients not amenable to curative treatment with surgery and\/or radiotherapy<\/li><li>Chronic myelomonocytic leukemia<\/li><li>Myelodysplastic syndrome<\/li><li>Nephroblastoma<\/li><li>Non-small cell lung cancer<\/li><li>Primary central nervous system lymphoma, Relapsed or refractory, non-immunocompromised<\/li><li>Small cell carcinoma of lung<\/li><\/ul>"}]},{"id":"923666-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Powder for Solution)<\/b><br\/>Use only in patients with neutrophil counts greater than or equal to 1500 cells\/mm(3) or greater and platelet counts 100,000 cells\/mm(3) or greater, and monitor blood cell counts, as severe myelosuppression can occur.<br\/><\/li><li><b>Oral (Capsule)<\/b><br\/>Use only in patients with neutrophil counts greater than or equal to 1500 cells\/mm(3) or greater and platelet counts 100,000 cells\/mm(3) or greater, and monitor blood cell counts, as severe myelosuppression can occur.<br\/><\/li><\/ul>"},{"id":"923666-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923666-s-3-9","title":"Contraindications","mono":"Severe hypersensitivity to topotecan  or any other component of the product <br\/>"},{"id":"923666-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warnings:<\/li><li>-- Neutropenia, including neutropenia associated with infection, febrile neutropenia, pancytopenia, and sepsis, has been reported; monitoring recommended and dosage adjustment or interruption may be necessary<\/li><li>-- Severe thrombocytopenia has been reported; monitoring recommended and dosage adjustment or interruption may be necessary<\/li><li>Dermatologic:<\/li><li>-- Extravasation, some cases severe, has been reported with IV use; immediately interrupt administration if suspected<\/li><li>Gastrointestinal:<\/li><li>-- Diarrhea, including severe and life-threatening diarrhea leading to hospitalization, has been reported with oral capsules; interruption of therapy and dosage adjustment may be necessary<\/li><li>-- Fatal typhlitis (neutropenic enterocolitis) may occur<\/li><li>Hematologic:<\/li><li>-- Severe anemia has been reported; monitoring recommended and therapy interruption may be necessary<\/li><li>Renal:<\/li><li>-- CrCl less than 50 mL\/min; dosage adjustment recommended for oral formulation<\/li><li>-- CrCl 20 to 39 mL\/min; dosage adjustment recommended for IV formulation<\/li><li>Reproductive:<\/li><li>-- Pregnancy; contraception recommended during and for 1 month after treatment<\/li><li>-- Use caution in female patients of reproductive potential, as topotecan may have both acute and long-term effects on fertility<\/li><li>-- Use caution in male patients of reproductive potential, as topotecan may damage spermatozoa, resulting in possible genetic and fetal abnormalities; contraception recommended during and for 3 months after treatment<\/li><li>Respiratory:<\/li><li>-- Interstitial lung disease, including fatalities, has been reported; monitoring recommended and discontinue if confirmed<\/li><li>Concomitant Use:<\/li><li>-- Do not initiate granulocyte colony stimulating factor within 24 hours after the last dose of IV topotecan<\/li><li>-- Avoid use of oral topotecan with P-glycoprotein inhibitors (eg, amiodarone, conivaptan, cyclosporine, erythromycin, ketoconazole, ritonavir, verapamil)<\/li><li>-- Avoid use of oral topotecan with breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine, eltrombopag)<\/li><\/ul>"},{"id":"923666-s-3-11","title":"Pregnancy Category","mono":"Topotecan: Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"923666-s-3-12","title":"Breast Feeding","mono":"Topotecan: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"923666-s-4","title":"Drug Interactions","sub":[{"id":"923666-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"923666-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Bosutinib (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Cabazitaxel (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carboplatin (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Cisplatin (probable)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Cyclosporine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diethylstilbestrol (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronabinol (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eltrombopag (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Estrone (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Filgrastim (theoretical)<\/li><li>Gefitinib (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Hesperidin (theoretical)<\/li><li>Hydrocortisone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mitoxantrone (theoretical)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Novobiocin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Pravastatin (theoretical)<\/li><li>Prazosin (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Saquinavir (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Smallpox Vaccine (established)<\/li><li>Sorafenib (theoretical)<\/li><li>Sulfasalazine (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tbo-Filgrastim (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telmisartan (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><li>Typhoid Vaccine (established)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Verapamil (theoretical)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"}]},{"id":"923666-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (IV, 49%; oral, 10% to 20%), Rash (IV, 16%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (IV, 5% to 22%), Constipation (5% to 29%), Diarrhea (IV, 6% to 32%; oral, 14% to 22%), Nausea (IV, 8% to 64%; oral, 27% to 33%), Stomatitis (6%), Vomiting (IV, 10% to 40%; oral, 19% to 21%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (Oral, 25%), Neutropenia, All grades (Oral, 83% to 91%), Thrombocytopenia, All grades (Oral, 81%)<\/li><li><b>Neurologic:<\/b>Asthenia (IV, 25%; oral, 3% to 7%), Headache (IV, 18%)<\/li><li><b>Respiratory:<\/b>Cough (IV, 15%), Dyspnea (IV, 6% to 22%)<\/li><li><b>Other:<\/b>Fatigue (IV, 29%; oral, 11% to 19%), Fever (28%, intravenous; 5% to 7%, oral)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea, Grade 3 or 4 (IV, 4%; oral, 0.4% to 22%), Neutropenic enterocolitis<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (IV, 6% to 42%; oral, 7% to 18%), Febrile neutropenia (23% to 28%), Neutropenia, Grade 3 or 4 (IV, 26% to 80%; oral, 24% to 33%), Thrombocytopenia, Grade 3 or 4 (IV, 7% to 29%; oral, 6% to 30%)<\/li><li><b>Respiratory:<\/b>Interstitial lung disease<\/li><\/ul>"},{"id":"923666-s-6","title":"Drug Name Info","sub":{"0":{"id":"923666-s-6-17","title":"US Trade Names","mono":"Hycamtin<br\/>"},"2":{"id":"923666-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Topoisomerase I Inhibitor<\/li><\/ul>"},"3":{"id":"923666-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923666-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"923666-s-7","title":"Mechanism Of Action","mono":"Topotecan hydrochloride is an anti-neoplastic agent that inhibits topoisomerase I from causing reversible single strand breaks in deoxyribonucleic acid (DNA) by attaching to the topoisomerase I-DNA complex. The drug exerts cytotoxic effects when it forms a ternary complex with topoisomerase I and DNA that interacts with replication enzymes, causing double stranded DNA damage during DNA synthesis.<br\/>"},{"id":"923666-s-8","title":"Pharmacokinetics","sub":[{"id":"923666-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability: Oral, 40%<\/li><li>Effect of food: minimal<\/li><\/ul>"},{"id":"923666-s-8-24","title":"Distribution","mono":"Protein binding: about 35% <br\/>"},{"id":"923666-s-8-25","title":"Metabolism","mono":"<ul><li>Plasma: pH dependent hydrolysis (alpha-beta-dihydroxycarboxylic acid (open-ring), inactive)<\/li><li>Plasma: topotecan lactone (active)<\/li><li>Hepatic: demethylation (N-desmethyl topotecan)<\/li><\/ul>"},{"id":"923666-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 33% (Oral)<\/li><li>Renal: about 30% (IV); 20% (Oral)<\/li><\/ul>"},{"id":"923666-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV: 2 hr to 3 hr; ORAL: 3 to 6 hr<\/li><li>Moderate renal impairment (creatinine clearance of 20 mL\/min to 39 mL\/min): about 5 hr (mean)<\/li><li>Liver Disease: 2.5 hr<\/li><\/ul>"}]},{"id":"923666-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of chemotherapy<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute each 4-mg vial with 4 mL of sterile water for injection and discard unused portion; dilute immediately with NS or D5W<\/li><li>once diluted, solution is stable for 24 hours under ambient lighting at 20 to 25 degrees C (68 to 77 degree F)<\/li><li>administer by IV infusion over 30 minutes<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>do not chew, crush, or divide capsules<\/li><li>take with or without food<\/li><\/ul><\/li><\/ul>"},{"id":"923666-s-10","title":"Monitoring","mono":"<ul><li>radiographic evidence of tumor response is indicative of efficacy<\/li><li>CBC with differential at baseline and frequently during therapy<\/li><li>signs and symptoms of interstitial lung disease (eg, cough, fever, dyspnea, and\/or hypoxia)<\/li><\/ul>"},{"id":"923666-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Powder for Solution: 4 MG<\/li><li>Intravenous Solution: 1 MG\/ML<\/li><\/ul><\/li><li><b>Hycamtin<\/b><br\/><ul><li>Intravenous Powder for Solution: 4 MG<\/li><li>Oral Capsule: 0.25 MG, 1 MG<\/li><\/ul><\/li><li><b>Novaplus Topotecan Hydrochloride<\/b><br\/><ul><li>Intravenous Powder for Solution: 4 MG<\/li><li>Intravenous Solution: 1 MG\/ML<\/li><\/ul><\/li><li><b>PremierPro Rx Topotecan Hydrochloride<\/b><br\/>Intravenous Powder for Solution: 4 MG<br\/><\/li><\/ul>"},{"id":"923666-s-12","title":"Toxicology","sub":[{"id":"923666-s-12-31","title":"Clinical Effects","mono":"<b>TOPOISOMERASE I INHIBITORS <\/b><br\/>OVERDOSE: Limited information available. Myelosuppression is the primary anticipated effect. ADVERSE EFFECTS: Myelosuppression as the dose-limiting toxicity, nausea, vomiting, diarrhea, abdominal pain, fever, dyspnea, increased coughing, headache, asthenia, paresthesia, alopecia and insomnia.<br\/>"},{"id":"923666-s-12-32","title":"Treatment","mono":"<b>TOPOISOMERASE I INHIBITORS<\/b><br\/><ul><li>Decontamination: DERMAL - Wash skin immediately with soap and water upon contact; flush mucous membranes copiously with water.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Myelosuppression: Severe neutropenia: filgrastim 5 mcg\/kg\/day subcutaneously. Transfusions as needed for thrombocytopenia, bleeding.<\/li><li>Fluid\/electrolyte balance regulation: Correct as indicated.<\/li><li>Pneumonitis: Monitor ABGs\/pulse oximetry, chest x-ray<\/li><li>Intrathecal injection: No clinical reports available, information derived from experience with other antineoplastics.  Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults.  Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free saline).  For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 mL\/hr).  Albumin (5%) and FFP have also been used for perfusion, and may be useful because of the protein binding of these agents. Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><li>Monitoring of patient: Monitor CBC, fluid and electrolytes and respiratory function in patients with pneumonitis.<\/li><\/ul>"},{"id":"923666-s-12-33","title":"Range of Toxicity","mono":"<b>TOPOISOMERASE I INHIBITORS<\/b><br\/>TOXICITY: A toxic dose has not been established. Toxicity is anticipated to be an extension of adverse events reported with therapeutic use. THERAPEUTIC DOSE: TOPOTECAN: 2.3 mg\/m(2)\/day once daily for 5 days and repeated every 21 days. IRINOTECAN: 125 to 180 mg\/m(2) IV over 90 minutes; usually combined with other chemotherapeutic agents. The schedule of therapy varies depending on which drug combination is being used. <br\/>"}]},{"id":"923666-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report an infection or other symptoms of myelosuppression.<\/li><li>Counsel female patient to use adequate contraception to prevent pregnancy during treatment and for at least 1 month after the last dose.<\/li><li>Instruct male patient to use adequate contraception to prevent pregnancy during treatment and for at least 3 months after the last dose.<\/li><li>Side effects may include nausea, diarrhea, vomiting, anorexia, alopecia, asthenia, or fatigue.<\/li><li>Instruct patient to report severe diarrhea.<\/li><li>Advise patient to report symptoms of interstitial lung disease.<\/li><\/ul>"}]}